drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
Anti-CD33 antibody–drug conjugate that delivers calicheamicin; after binding CD33 and internalization, releases calicheamicin to induce DNA double-strand breaks and apoptosis in AML blasts.
nci_thesaurus_concept_id
C1806
nci_thesaurus_preferred_term
Gemtuzumab Ozogamicin
nci_thesaurus_definition
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)
drug_mesh_term
Gemtuzumab Ozogamicin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-CD33 monoclonal antibody linked to calicheamicin; after CD33 binding and internalization, calicheamicin is released to bind the DNA minor groove, inducing double-strand breaks and apoptosis in CD33-positive AML cells.
drug_name
gemtuzumab ozogamicin
nct_id_drug_ref
NCT05716009